| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55ced2e391cfc43498bb74416303177f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abfd9a775bbcc4ee61e3f4c3b53fb303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43e13815e78955c37ca84ad1f9a92534
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9a09b0cf619a1445c6329043d926c8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06602a812147bfec2455b7940dde6057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66aeee44b2587b3b10ab88227b415f56 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90f96e3a310e57923c14b08e7ae1200e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef844282744d3ed19fe06ec5782ff6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fd8ed01c62130327f94c40ed0f900bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cff3150837693378f5ec8bc5ee7b97f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba0588b8c39405d8433b9d524e8237da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc888eee819b0e84c92e43c4bbfb8248 |
| publicationDate |
2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012078931-A2 |
| titleOfInvention |
Gene signatures for prediction of therapy-related myelodysplasia and methods for identification of patients at risk for development of the same |
| abstract |
In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level. |
| priorityDate |
2010-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |